Home

Company

Products

Press

Purchase

Contact

Company Snapshot

• Biotechnology company developing enabling technology platforms and enhanced therapeutic products for preventing and treating certain cancers, infectious diseases, and Central Nervous System (CNS) disorders

• Awarded several peer-reviewed, competitive SBIR Grants from NIH and NSF, and ATP grants from the NIST, Department of Commerce

• Enabling technology platforms, nanotechnologies and enhanced therapeutic products covered by 36 issued US and international patents, and 22 pending patent applications

• History of collaborations with multinational companies such as Novartis, Bayer, Bristol-Myers Squibb, Eli Lilly, Baxter Healthcare, Sigma-Aldrich and leading academic institutions

Recent Achievements

• Completion of a successful multicenter Phase II/III randomized, placebo-controlled, 644-patient clinical trial of Zindol®, an enhanced ginger product in gel capsules, as an adjunctive therapy for chemotherapy induced nausea and vomiting (CINV)

• Nanoencapsulation of siRNA using Aphios' SuperFluids™ CFN technology to improve its delivery and therapeutic efficacy in collaboration with a top five multinational pharmaceutical company


• Frost & Sullivan 2009 North American Excellence in Healthcare Technology Innovation of the Year Best Practices Award in the field of Enhanced Nanodrug Therapeutic Systems for SuperFluids™ nanodrug solubility, encapsulation and delivery platforms

Enabling Technology Platforms

• Drug Discovery: Patented SuperFluids™ CXF polarity-guided fractionation tech-nology for rapid discovery of drugs from marine microorganisms and medicinal plants

• Drug Manufacturing: Patented SuperFluids™ CXP technology for manufacturing natural pharmaceuticals such as paclitaxel, bryostatin 1, betulinic acid, cyclopamine

• Drug Delivery: Patented nanotechnologies platforms – Protein Nanoparticles, Phospholipid Nanosomes and Polymer Nanospheres for small molecules, hydro-phobic compounds, siRNA, therapeutic proteins and peptides, and vaccine antigens

• Drug Safety: Patented SuperFluids™ CFI pathogen (virus) inactivation for inactivation of both enveloped and nonenveloped virus without damaging proteins

Enhanced Therapeutic Products

• Zindol® for chemotherapy induced nausea and vomiting (CINV); APH-0703 for Alzheimer’s Disease and Cognitive Disorders, AMPI-109 is a nanosomal formulation of a nontoxic Vitamin-D derivative for hormone refractory prostate cancer (HRPCA); APH-0701 for HIV Latency; APH-0911 is a Taxotere? prodrug encapsulated in biodegradable polymer nanospheres for cancer chemotherapy or chemoprevention

• Infectious disease portfolio includes several anti-influenza, anti-HIV, and anti-smallpox hits, and marine antimicrobial compounds that are effective against plaque and gingivitis and multi-drug resistant human pathogens (MRSA, VRE)

• Quality-of-life medicines (nutraceuticals) for emotional well-being, calming stomachs and healthy digestion, and healthy prostate function and hair follicles (US Patents)

Management and Directors

• Click here

For more information about Aphios Corporation, please click here.